Protocols
5 protocol(s) meet the specified criteria
PI: Dittus, Christopher
Protocol No.TitleStatus
GO29383A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR ATEZOLIZUMAB ADMINISTERED WITH OBINUTUZUMAB OR TAZEMETOSTAT IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAOpen
LCCC1503A Phase I/Ib Study of Alisertib plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell LymphomasOpen
MT-3724-NHL-001-USPharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients with Relapsed non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic LeukemiaOpen
NCI9534A phase I trial of ibrutinib plus PD 0332991 (palbociclib) in patients with previously treated mantle cell lymphomaOpen
SGN19A-003A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplantOpen